Natixis Advisors’s Vir Biotechnology VIR Stock Holding History

Natixis Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,187	Closed	-$438K	–	1518
2022 Q2	$438K	Buy	+17,187	New	+$401K	﹤0.01%	1310

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's VIR Position: Q3 2022 in Review

Natixis Advisors sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 17,187 shares — an estimated $438K sold.

Natixis Advisors first reported a position in VIR in Q2 2022 and held it in 1 quarter. The position peaked at $438K in Q2 2022. 221 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

Natixis Advisors reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
Natixis Advisors sold 17,187 Vir Biotechnology shares in Q3 2022, an estimated $438K.
Natixis Advisors first reported a position in Vir Biotechnology in Q2 2022 and held it in 1 quarter.
Natixis Advisors's Vir Biotechnology position peaked at $438K in Q2 2022.
221 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Natixis Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.